Skip to main content

In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo.

Publication ,  Journal Article
Pisetsky, DS
Published in: Ann Intern Med
August 2023

Smith RM, Jones RB, Specks U, et al; RITAZAREM co-investigators. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis. 2023;82:937-944. 36958796.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

August 2023

Volume

176

Issue

8

Start / End Page

JC95

Location

United States

Related Subject Headings

  • Rituximab
  • Remission Induction
  • Recurrence
  • Immunosuppressive Agents
  • Humans
  • General & Internal Medicine
  • Cyclophosphamide
  • Chronic Disease
  • Azathioprine
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pisetsky, D. S. (2023). In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo. Ann Intern Med, 176(8), JC95. https://doi.org/10.7326/J23-0057
Pisetsky, David S. “In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo.Ann Intern Med 176, no. 8 (August 2023): JC95. https://doi.org/10.7326/J23-0057.
Pisetsky, David S. “In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo.Ann Intern Med, vol. 176, no. 8, Aug. 2023, p. JC95. Pubmed, doi:10.7326/J23-0057.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

August 2023

Volume

176

Issue

8

Start / End Page

JC95

Location

United States

Related Subject Headings

  • Rituximab
  • Remission Induction
  • Recurrence
  • Immunosuppressive Agents
  • Humans
  • General & Internal Medicine
  • Cyclophosphamide
  • Chronic Disease
  • Azathioprine
  • 3202 Clinical sciences